The federal test turns on chemistry and measured effect, not on which psychedelic inspired the molecule. Johnson & Johnson is leading an $85M round for Delix Therapeutics on the strength of that distinction.
Novel neuroplastogens do not appear on federal controlled substance schedules today. They are not explicitly classified as Schedule I or Schedule II under the Controlled Substances Act (CSA). These molecules draw chemical inspiration from classic psychedelics, but federal drug law evaluates a novel compound through specific administrative listings and statutory analogue standards, not chemical lineage alone.
Understanding whether a neuroplastogen is legal means separating clinical-research authorization from commercial consumer availability. Biotechnology sponsors can advance these candidates under FDA investigational clearances, but no neuroplastogen has received federal marketing approval for patient prescription outside an authorized clinical trial. Readers tracking the broader regulatory environment can compare these statutory standards against our guide to what psychedelics are legal in the US and our psychedelic legalization tracker.
A neuroplastogen is a synthetic compound engineered to stimulate neural plasticity by activating serotonin 5-HT2A receptors without inducing psychedelic hallucinations, sedation, or dissociation. Biotechnology developer Delix Therapeutics coined the term. It describes molecules built to preserve the neurostructural benefits of classic psychedelics while eliminating the acute perceptual alterations that require supervised clinical monitoring. In preclinical animal studies, these molecules reduced depressive-like behavior on standard antidepressant screening tests without producing measurable hallucinogenic markers.
The primary pharmacological distinction sits at the serotonin 5-HT2A receptor interface. Classic hallucinogens like psilocybin, dimethyltryptamine (DMT), and 5-MeO-DMT bind to 5-HT2A receptors with high functional efficacy. That triggers downstream signaling that disrupts sensory gating and produces the altered perception, sense of time, and sense of self that define a psychedelic experience. A neuroplastogen selectively activates different receptor pathways instead. Those pathways drive dendritic spine growth and synaptic remodeling while staying below the threshold needed to produce sensory distortion.
Delix Therapeutics designed its lead candidate, zalsupindole (also designated DLX-001), around this signaling separation. Zalsupindole is an orally bioavailable isotryptamine structurally derived from a combination of 5-methoxy-N,N-dimethylisotryptamine (5-MeO-isoDMT) and alpha-methylisotryptamine. In Phase 1 human trials, it met its safety endpoints without producing dissociative episodes. Phase Ib data from 18 patients with major depressive disorder (MDD) then showed effects on biological markers of neural plasticity. Delix said the antidepressant effects appeared quickly and lasted.
Federal controlled-substance scheduling requires explicit listing by name or chemical structure. A novel neuroplastogen is not automatically prohibited just because it resembles a scheduled drug. Under 21 U.S.C. § 812, Congress and the Drug Enforcement Administration (DEA) maintain schedules of controlled substances, each subject to strict manufacturing, handling, and distribution quotas. Zalsupindole is not on any of them. Neither it nor other neuroplastogen molecules appear on Schedule I through Schedule V by name, so none are scheduled controlled substances under direct statutory listing today.
A novel compound can still fall under federal jurisdiction through the Federal Analogue Act, codified at 21 U.S.C. § 802(32). The test has two parts. First, the structure must closely resemble a Schedule I or Schedule II drug. Second, the compound must produce a stimulant, depressant, or hallucinogenic effect on the central nervous system substantially similar to or greater than that drug’s effect. The same prong is also met if the sponsor represents or intends that the drug produces such an effect.
The dual-prong requirement sets a real barrier. Structural similarity alone is not enough. Federal prosecutors might point to zalsupindole’s resemblance to scheduled tryptamines like 5-MeO-DMT, but the government must also prove the effects prong. Zalsupindole is engineered specifically to lack hallucinogenic, stimulant, or depressant effects at therapeutic doses, which gives it a credible defense there. A substance that does not alter the central nervous system the way a Schedule I hallucinogen does fails the statutory test.
Federal law carves out an exception for legitimate research. Conduct under an active investigational new drug (IND) exemption is excluded from treatment as a controlled-substance analogue. Under 21 U.S.C. § 802(32)(C), the Federal Analogue Act excludes any substance covered by an IND exemption in effect under Section 505 of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. § 355). That protects a sponsor with FDA authorization from federal analogue enforcement during the trial.
That protection let Delix Therapeutics run human trials on zalsupindole without DEA Schedule I research registration. Standard Schedule I psychedelic research needs DEA site licenses, approved vault storage, and rigid inventory quotas. Those requirements slow a trial down. Operating instead under the IND exemption, Delix secured FDA clearance for a Phase II trial design that includes at-home dosing.
At-home dosing is a real departure from how conventional psychedelic medicine is regulated. Schedule I hallucinogens like psilocybin or MDMA cannot legally be dispensed for unsupervised patient self-administration outside an institutional setting. Even approved psychiatric interventions like esketamine carry heavy regulatory friction. As explained in our ketamine therapy guide, the FDA requires patients receiving esketamine to remain under in-clinic healthcare supervision for at least two hours because of sedation and dissociation risk.
Corporate investment in neuroplastogens accelerated when healthcare conglomerate Johnson & Johnson agreed to lead an 85 million dollar Series C financing round for Delix Therapeutics. The financing terms established a 190 million dollar pre-money valuation for Delix Therapeutics and granted Johnson & Johnson a right of first negotiation following Phase II clinical trial readouts. This right of first negotiation encompasses both the lead zalsupindole program and Delix Therapeutics as an entire corporate entity. This agreement signals strong institutional interest in non-hallucinogenic psychiatric interventions.
The transaction marks the formal entry of Johnson & Johnson into non-hallucinogenic psychedelic-inspired drug development. Johnson & Johnson already possesses deep commercial experience in psychiatric novel molecules through its commercialization of Spravato (esketamine), an FDA-approved nasal spray for treatment-resistant depression. However, Spravato requires a restrictive Risk Evaluation and Mitigation Strategy (REMS) program. The REMS protocol mandates that healthcare providers administer Spravato only in certified medical facilities. Certified staff must monitor patients for blood pressure spikes and dissociative symptoms for two hours before release.
Zalsupindole targets depression without imposing the substantial labor overhead associated with REMS clinic monitoring. If Phase II trials confirm that zalsupindole provides durable antidepressant efficacy without inducing dissociation, Delix Therapeutics could pursue commercial approval as a conventional take-home oral tablet. This distinction explains why venture capital and pharmaceutical firms active in psychedelic stocks and ETFs are dedicating capital to neuroplastogen platforms that eliminate clinical administration bottlenecks.
Neuroplastogens remain unapproved investigational compounds that cannot be legally sold, prescribed, or compounded outside of authorized clinical research protocols. While zalsupindole does not appear on DEA controlled substance schedules, the lack of an affirmative Schedule I listing does not create an over-the-counter consumer market. Federal law prohibits the commercial interstate distribution of unapproved new drugs under the Federal Food, Drug, and Cosmetic Act, restricting lawful patient access strictly to active clinical trial sites.
Biotechnology investors must also recognize that federal regulatory posture can evolve if post-market surveillance reveals unexpected abuse liability. If subsequent clinical trials or real-world human data suggest that a neuroplastogen compound possesses reinforcing properties or unrecognized central nervous system effects, the DEA retains administrative authority under 21 U.S.C. § 811 to initiate formal scheduling proceedings. Furthermore, state-level legislation can independently classify novel chemical classes. Readers tracking jurisdictional variations can monitor our state-by-state psychedelic legal status tool to follow legislative developments.
Finally, the emergence of the neuroplastogen sector does not alter the federal legal classification of classic psychedelic molecules. Compounds such as psilocybin, MDMA, lysergic acid diethylamide (LSD), DMT, 5-MeO-DMT, and ibogaine remain strictly listed under Schedule I of the Controlled Substances Act. Developing non-hallucinogenic derivatives creates a parallel clinical pathway for psychiatry, but it leaves the statutory prohibitions governing traditional psychedelic medicine entirely intact. Readers who want to track what happens next can follow federal and state scheduling changes with our psychedelic legalization tracker.
Zalsupindole does not appear on any Drug Enforcement Administration (DEA) controlled substance schedule today. Because zalsupindole is not explicitly scheduled by name and clinical research proceeds under an authorized investigational new drug (IND) exemption, it is not treated as a Schedule I substance during clinical development. Federal regulators have not issued a public determination on its post-approval scheduling status.
No. No neuroplastogen molecule has received marketing approval from the FDA for commercial medical use. Outside authorized clinical trials, manufacturing or distributing an unapproved investigational drug violates federal law.
The Federal Analogue Act requires both substantial chemical similarity and a substantially similar stimulant, depressant, or hallucinogenic effect compared to a scheduled compound. Because true neuroplastogens are engineered to activate 5-HT2A receptors without producing hallucinogenic or dissociative effects, sponsors have a real argument that they fail the effects prong. Separately, 21 U.S.C. § 802(32)(C) excludes FDA-authorized investigational research from analogue treatment.
No. Psilocybin, MDMA, LSD, and 5-MeO-DMT remain listed under Schedule I of the Controlled Substances Act regardless of any neuroplastogen's status. Neuroplastogen research opens a separate, unscheduled development pathway for novel derivatives without altering the law governing the parent compounds.
Get psychedelic industry & legal research & policy updates
New trials, FDA decisions, and legal changes for psychedelic industry & legal — delivered when they happen.
Suggest a tool, topic, or improvement that would make this site more useful.